Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.

doi:10.1002/ajh.26731

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.

American journal of hematology - 1 Dec 2022

Rivera Daniel, Kim Kunhwa, Kanagal-Shamanna Rashmi, Borthakur Gautam, Montalban-Bravo Guillermo, Daver Naval, Dinardo Courtney, Short Nicholas J, Yilmaz Musa, Pemmaraju Naveen, Takahashi Koichi, Jabbour Elias J, Pierce Sherry, Konopleva Marina, Bhalla Kapil, Garcia-Manero Guillermo, Ravandi Farhad, Kantarjian Hagop, Kadia Tapan M

Abstract excerpt

Activating mutations in RAS have been reported in about 10-15% of patients with AML; previous studies have not identified a prognostic significance. However, RAS mutations have emerged as a potential resistance mechanism to treatment with inhibitors of FLT3, IDH, and BCL2. We aimed to determine the characteristics and outcomes of patients with RAS-mutated (RAS-mut) AML across therapy subsets of 1410 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Genes, ras

Share to Karyotype

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to ras Proteins

Source

Open in PubMed

Identifiers

PMID: 36117258
DOI: 10.1002/ajh.26731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.PMID 36117258Read ↗

Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia.Semantic proximity Read ↗

RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis.Semantic proximity Read ↗

Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.Semantic proximity Read ↗

RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.Semantic proximity Read ↗

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.Semantic proximity Read ↗

[Clinical characteristics and prognostic implications of RAS mutations in newly diagnosed acute myeloid leukemia with normal karyotype based on next-generation sequencing analysis].Semantic proximity Read ↗

[Clinical Significance of RAS Gene Mutations in Patients with Acute Myeloid Leukemia].Semantic proximity Read ↗

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.Semantic proximity Read ↗

Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid LeukemiaSemantic proximity Read ↗

Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.Semantic proximity Read ↗

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Semantic proximity Read ↗

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.